Australia markets closed
  • ALL ORDS

    7,111.40
    +32.50 (+0.46%)
     
  • ASX 200

    6,824.70
    +24.30 (+0.36%)
     
  • AUD/USD

    0.7728
    +0.0011 (+0.15%)
     
  • OIL

    52.15
    -0.12 (-0.23%)
     
  • GOLD

    1,862.90
    +6.70 (+0.36%)
     
  • BTC-AUD

    44,806.66
    +1,447.49 (+3.34%)
     
  • CMC Crypto 200

    696.54
    +19.64 (+2.90%)
     
  • AUD/EUR

    0.6360
    +0.0024 (+0.39%)
     
  • AUD/NZD

    1.0721
    -0.0016 (-0.15%)
     
  • NZX 50

    13,399.10
    +65.67 (+0.49%)
     
  • NASDAQ

    13,366.40
    0.00 (0.00%)
     
  • FTSE

    6,631.13
    -63.94 (-0.96%)
     
  • Dow Jones

    30,928.21
    -68.77 (-0.22%)
     
  • DAX

    13,690.19
    -183.78 (-1.32%)
     
  • Hang Seng

    30,159.01
    +711.16 (+2.41%)
     
  • NIKKEI 225

    28,822.29
    +190.84 (+0.67%)
     

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fortress Biotech, Inc. (FBIO) on Behalf of Investors

·3-min read

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) investors concerning the Company’s possible violations of the federal securities laws.

If you suffered a loss on your Fortress investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/fortress-biotech-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

Fortress develops and commercializes pharmaceutical and biotechnology products. In December 2019, the Company's majority-controlled subsidiary, Avenue Therapeutics, Inc. ("Avenue"), submitted a New Drug Application ("NDA") for its intravenous ("IV") Tramadol product to the U.S. Food and Drug Administration ("FDA") for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

On October 12, 2020, Avenue disclosed receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for its IV Tramadol product. Specifically, the FDA advised Avenue that "it cannot approve the application in its present form" because "IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population." Specifically, the CRL stated: "[I]f a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed. The likely choice would be another opioid, which would result in opioid 'stacking' and increase the likelihood of opioid-related adverse effects."

On this news, Fortress's stock price fell $1.00 per share, or 23.98%, to close at $3.17 per share on October 12, 2020, thereby injuring investors.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding Fortress should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005333/en/

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com
shareholders@glancylaw.com